Corbus Pharmaceuticals Holdings (CRBP) Interest Expenses (2013 - 2025)

Corbus Pharmaceuticals Holdings' Interest Expenses history runs 13 years deep, the most recent figure standing at $371000.0 for Q4 2025.

• On a quarterly basis, Interest Expenses rose 615.28% year-over-year to $371000.0 in Q4 2025; TTM through Dec 2025 was $371000.0, a 84.04% decrease from a year earlier, with the FY2025 full-year figure at $371000.0, down 86.83% from the prior year.
• Interest Expenses slipped to $371000.0 in Q4 2025 per CRBP's latest filing, from $3.0 million in the prior quarter.
• Across five years, Interest Expenses topped out at $38.8 million in Q3 2021 and bottomed at -$223417.0 in Q4 2022.
• The 5-year median for Interest Expenses is $2.8 million (2024), against an average of $11.0 million.
• Across the five-year window, Interest Expenses sank 151.32% in 2022 and surged 615.28% in 2025, its largest moves.
• Year by year, Interest Expenses stood at $435366.0 in 2021, then sank by 151.32% to -$223417.0 in 2022, then jumped by 377.96% to $621000.0 in 2023, then sank by 111.59% to -$72000.0 in 2024, then jumped by 615.28% to $371000.0 in 2025.
• Per Business Quant, the three latest CRBP Interest Expenses figures stand at $371000.0 (Q4 2025), $3.0 million (Q1 2025), and -$72000.0 (Q4 2024).